Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
Cochrane Database of Systematic Reviews2007Iss. 1, pp. CD005166–CD005166
Citations Over Time
Abstract
At present, there is insufficient data to either support or refute the use of drugs improving insulin resistance for patients with NAFLD, although current limited information suggests a favourable role of drugs improving insulin resistance. It is advisable to carry out large randomised trials on this topic employing clinically relevant outcome measures and adequate methodology, including blinded outcome assessment.
Related Papers
- → Review article: is non‐alcoholic fatty liver disease a spectrum, or are steatosis and non‐alcoholic steatohepatitis distinct conditions?(2012)215 cited
- → Prevalence of fatty liver in metabolic syndrome(2020)16 cited
- → Non-alcoholic steatohepatitis(2006)15 cited
- → Categorization and complication of non-alcoholic fatty liver disease(2022)1 cited
- → Mo1015 Liver Function Breath Tests for Differentiation of Steatohepatitis From Simple Fatty Liver in Patients With Non-Alcoholic Fatty Liver Disease(2013)